Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW. Snead JL, et al. Among authors: deininger mw. Blood. 2009 Oct 15;114(16):3459-63. doi: 10.1182/blood-2007-10-113969. Epub 2009 Aug 25. Blood. 2009. PMID: 19706883 Free PMC article.
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW. Willis SG, et al. Among authors: deininger mw. Blood. 2005 Sep 15;106(6):2128-37. doi: 10.1182/blood-2005-03-1036. Epub 2005 May 24. Blood. 2005. PMID: 15914554 Free article.
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ. Press RD, et al. Among authors: deininger mw. Blood. 2006 Jun 1;107(11):4250-6. doi: 10.1182/blood-2005-11-4406. Epub 2006 Feb 7. Blood. 2006. PMID: 16467199 Free PMC article. Clinical Trial.
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Griswold IJ, et al. Among authors: deininger mw. Mol Cell Biol. 2006 Aug;26(16):6082-93. doi: 10.1128/MCB.02202-05. Mol Cell Biol. 2006. PMID: 16880519 Free PMC article.
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ. Loriaux MM, et al. Among authors: deininger mw. Blood. 2008 May 1;111(9):4788-96. doi: 10.1182/blood-2007-07-101394. Epub 2008 Feb 5. Blood. 2008. PMID: 18252861 Free PMC article.
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW. O'Hare T, et al. Among authors: deininger mw. Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5507-12. doi: 10.1073/pnas.0800587105. Epub 2008 Mar 26. Proc Natl Acad Sci U S A. 2008. PMID: 18367669 Free PMC article.
264 results